As of November 7, 2026, Moleculin Biotech, Inc. is a publicly traded company (Nasdaq: MBRX). The largest holder reporting an active stake on Schedule 13D is Walter Klemp V, the chief executive and president, at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Jonathan P. Foster, the chief financial officer (6.3%) (Schedule 13D, August 25, 2026).
Is this your company?
About to sign with, pay or invest in Moleculin Biotech, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Moleculin Biotech, Inc. a real, registered company?
- Moleculin Biotech, Inc. files with the SEC under CIK 1659617 (its SEC filings).
- Its shares are listed under the ticker MBRX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Houston, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Moleculin Biotech, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Foster Jonathan P. (filed 2026-08-25).
Who are Moleculin Biotech, Inc.'s owners and officers?
Moleculin Biotech, Inc.: incorporated in Delaware; business address in Houston, Texas; industry Pharmaceutical Preparations (Schedule 13D, 2026-08-25).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-08-25 | Foster Jonathan P. | 6.3% |
| Schedule 13D, 2026-08-25 | Klemp Walter V | 9.9% |
| Schedule 13G, 2026-08-10 | Cvi Investments, Inc. | 9.9% |
| Schedule 13G, 2026-08-06 | Mitchell P. Kopin | 4.99% |
| Schedule 13G/A, 2025-08-14 | Armistice Capital, LLC | 4.99% |
Questions about who owns Moleculin Biotech, Inc.
Who owns Moleculin Biotech, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Moleculin Biotech, Inc.: Klemp Walter V (9.9%, Schedule 13D, filed 2026-08-25), Cvi Investments, Inc. (9.9%, Schedule 13G, filed 2026-08-10) and Foster Jonathan P. (6.3%, Schedule 13D, filed 2026-08-25).
Who are the largest shareholders of Moleculin Biotech, Inc.?
By the share each holder's latest filing reports, the largest holders of Moleculin Biotech, Inc. on this page are Klemp Walter V (9.9%), Cvi Investments, Inc. (9.9%) and Foster Jonathan P. (6.3%).
When did Klemp Walter V buy into Moleculin Biotech, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Klemp Walter V on this page is the Schedule 13D, filed 2026-08-25, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Moleculin Biotech, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Moleculin Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Moleculin Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Moleculin Biotech, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 36,203 shares (0.19% of shares outstanding) (Form 4, 2026-11-06).
- , the chief financial officer: 20,291 shares (0.10% of shares outstanding) (Form 4, 2026-11-06).
- , the chief science officer: 8,718 shares (0.04% of shares outstanding) (Form 4, 2026-11-06).
Shares outstanding: 19,477,380 as of 2026-08-06, from the company's latest SEC cover page.
How much has Moleculin Biotech, Inc. raised?
Latest IPO step: Moleculin Biotech, Inc. amended its IPO registration (S-1/A, 2026-07-31).
IPO filings: S-1/A, 2026-07-31, S-1/A, 2026-07-30, S-1, 2026-07-29, 424B4, 2025-06-23, S-1/A, 2025-06-16; ticker MBRX on Nasdaq Capital Market.
Keep reading
More on Moleculin Biotech, Inc. and the records around it.
Moleculin Biotech, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/moleculin-biotech